- Home
- BJRI vs ABVX Comparison
BJRI vs ABVX Comparison
Compare BJRI & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BJRI
- ABVX
- Stock Information
- Founded
- BJRI 1978
- ABVX 2013
- Country
- BJRI United States
- ABVX France
- Employees
- BJRI N/A
- ABVX N/A
- Industry
- BJRI Restaurants
- ABVX
- Sector
- BJRI Consumer Discretionary
- ABVX
- Exchange
- BJRI Nasdaq
- ABVX Nasdaq
- Market Cap
- BJRI 797.9M
- ABVX 722.3M
- IPO Year
- BJRI 1996
- ABVX N/A
- Fundamental
- Price
- BJRI $35.93
- ABVX $7.91
- Analyst Decision
- BJRI Hold
- ABVX Strong Buy
- Analyst Count
- BJRI 5
- ABVX 7
- Target Price
- BJRI $39.25
- ABVX $37.86
- AVG Volume (30 Days)
- BJRI 365.5K
- ABVX 152.2K
- Earning Date
- BJRI 05-01-2025
- ABVX 03-24-2025
- Dividend Yield
- BJRI N/A
- ABVX N/A
- EPS Growth
- BJRI N/A
- ABVX N/A
- EPS
- BJRI 0.70
- ABVX N/A
- Revenue
- BJRI $1,357,302,000.00
- ABVX $9,676,417.00
- Revenue This Year
- BJRI $5.58
- ABVX $31.67
- Revenue Next Year
- BJRI $3.14
- ABVX $759.77
- P/E Ratio
- BJRI $51.33
- ABVX N/A
- Revenue Growth
- BJRI 1.81
- ABVX 100.87
- 52 Week Low
- BJRI $27.61
- ABVX $5.50
- 52 Week High
- BJRI $41.72
- ABVX $17.02
- Technical
- Relative Strength Index (RSI)
- BJRI 46.77
- ABVX 59.77
- Support Level
- BJRI $36.31
- ABVX $6.95
- Resistance Level
- BJRI $38.60
- ABVX $8.47
- Average True Range (ATR)
- BJRI 1.65
- ABVX 0.41
- MACD
- BJRI -0.16
- ABVX 0.06
- Stochastic Oscillator
- BJRI 18.57
- ABVX 63.16
About BJRI BJ's Restaurants Inc.
BJ's Restaurants Inc is involved in the business of owning and operating restaurants. The company operates in one operating segment that is casual dining company-owned restaurants. It has geographic presence only in the United States of America.
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. They are evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two most common forms are UC and CD.